NYSE · CRL

Charles River Laboratories International, Inc.

$226.58 -$2.71 (-1.18%) 1D After hours

Key Metrics

$11.04B
Market cap
P/E · TTM
$4.03B
Revenue · TTM
−$184.65M
Net income
EPS · TTM $-3.63
Dividend yield
Free cash flow $391.29M
Beta · 1Y 1.29
EBITDA · TTM $295.82M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 28
    The stock moved +10.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 28
  • May 18
    From its Feb 2 high, the share price fell 30%.

    Peak close $213.22 on Feb 2; trough close $149.93 on May 18. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -30%
  • Mar 12
    The stock moved -9.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 12

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$11.04B
Enterprise value$13.52B
Shares outstanding48.2M
52-wk range$144.26 – $238.85
Avg volume · 20D667.0K
Net cash −$2.48B
Book value / share$57.83
IndustryServices-Commercial Physical & Biological Research
ExchangeNYSE
About Charles River Laboratories International, Inc.
IPO dateJun 23, 2000
Employees19700

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.74
P/FCF28.23
EV/EBITDA45.71
EV/Sales3.36
Graham №

Profitability

Gross
Operating -1.3%
Net -4.6%
FCF 9.7%
ROE / ROIC -5.8% · —

Financial Health

Current ratio1.36
Quick ratio1.03
Debt / equity0.91
Debt / EBITDA 9.03
Net cash −$2.48B
Working capital$395.10M

Cash Flow · TTM

Operating CF $607.03M
Capex −$215.74M
Free cash flow $391.29M
Buybacks $215.83M
Dividends paid
Shareholder yield 2.0%

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

2.2
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-28 · computed by TickerWolf from SEC filings